SCHEMBL2185107

SCHEMBL2185107

CC(C)(C)OC(=O)NC1CCCN(c2ccnc3ccc(Br)cc23)C1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.52
PDE10A Q9Y233 2/20 0.49
NCF1 P14598 1/20 0.47
BTK Q06187 4/20 0.47
JAK3 P52333 2/20 0.47
SYK P43405 1/20 0.45
AURKA O14965 3/20 0.44
PDPK1 O15530 3/20 0.44
AURKB Q96GD4 3/20 0.44
KDM4D Q6B0I6 1/20 0.44
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
MET P08581 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
EGFR P00533 1/20 0.41
LCK P06239 1/20 0.41
RET P07949 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185110 1.00 MAP4K4 (0.52) MAP4K4PDE10ANCF1BTKJAK3
SCHEMBL21190346 0.90 NCF1 (0.52) MAP4K4PDE10ANCF1SYKKDM4D
SCHEMBL2185339 0.85 BTK (0.53) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL2185335 0.85 BTK (0.53) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL20293064 0.85 MAP4K4 (0.48) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL20293260 0.85 MAP4K4 (0.48) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL2205363 0.83 MAP4K4 (0.47) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL2185869 0.83 MAP4K4 (0.47) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL2185867 0.83 MAP4K4 (0.47) MAP4K4PDE10ABTKJAK3SYK
SCHEMBL2205365 0.83 MAP4K4 (0.47) MAP4K4PDE10ABTKJAK3SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735424-B2 Bicyclic kinase inhibitors NOVARTIS AG (CH) 2014-05-27 US disclosed
US-20110195980-A1 Bicyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
US-20110195980-A1 Bicyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed
EP-2342190-A1 BICYCLIC KINASE INHIBITORS Novartis AG (CH) 2011-07-13 EP disclosed
WO-2010026121-A1 BICYCLIC KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195980-A1 Bicyclic Kinase Inhibitors PIM1, PIM2, PIM3 MAP4K4 115/4885PDE10A 3745/4885NCF1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.